Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

Deal For Yervoy Biosimilar Worth Up To $301m; Offers Synergy With Nivolumab

 
• By Dave Wallace
  
Sandoz and Henlius have shaken hands on a deal for ipilimumab (Shutterstock)

More from Deals

More from Strategy